Examining the Pharmacokinetics and Pharmacodynamics of LAI Antipsychotics: How Best to Individualize Treatment

Examining the Pharmacokinetics and Pharmacodynamics of LAI Antipsychotics: How Best to Individualize Treatment

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Alkermes, Inc.

FACULTY

Roger W. SommiRoger W. Sommi, Pharm.D., BCPP, FCCP
Professor and Associate Dean
Division of Pharmacy Practice, Administration and Psychiatry
University of Missouri, Kansas City Schools of Pharmacy and Medicine
Kansas City, MO

FINANCIAL DISCLOSURE

Roger W. Sommi, Pharm.D., BCPP, FCCP has disclosed the following: Received grants/research support from Alkermes, Inc., Neurocrine Biosciences, Ortho-McNeil-Janssen Pharmaceuticals, Otsuka America Pharmaceutical, Inc., and Teva Pharmaceutical Industries Ltd.; Served as clinical investigator for Alkermes, Inc., Auspex Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Otsuka America Pharmaceutical, Inc. and Teva Pharmaceutical Industries Ltd.; Served as consultant for Alkermes, Inc., and Neurocrine Biosciences; and, served on speaker's bureaus for Alkermes, Inc. and Sunovion Pharmaceuticals Inc.

The clinical reviewer, Charles F. Caley, PharmD, has disclosed that he has served on an advisory board for Alkermes, Inc.

Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN-RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENTS

acpePHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-18-014-H01-P

Credits: 1.0 hours (0.10 ceu)
Published: May 14, 2018
Expires: May 14, 2019
Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 60 minutes

Type of Activity: Application

TARGET AUDIENCE

This accredited activity has been designed for oncology pharmacists.

HOW TO EARN CREDIT

During the period May 14, 2018 through May 14, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

To inform and educate psychiatric and neurologic pharmacists on the efficacy, safety, and appropriate use of LAI antipsychotics in selected patients with schizophrenia.

EDUCATIONAL OBJECTIVES

Upon completion of this program, participants should be better able to:

  • Identify patients who would benefit from LAI antipsychotics
  • Evaluate comparative data for long-acting injectable (LAI) antipsychotics
  • Compare the pharmacokinetics and pharmacodynamics of available LAI antipsychotics
  • Implement effective treatment plans that promote adherence and maximize patient outcomes

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

DISCLOSURE OF UNLABELED USE AND DISCLAIMER

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC. or Alkermes, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.

Postgraduate Healthcare Education, LLC (PHE) is the source of Power-Pak C.E.® continuing education for health care professionals. Our accredited programs assist in meeting the requirements of licensure. PHE provides continuing education for the broad spectrum of health care professionals. This site features a searchable database of accredited Power-Pak C.E.® courses on important topics for today's health care professionals.

PHE customizes Power-Pak C.E.® online for each visitor by creating a personal participant profile. Registered participants may update their contact information, take an exam, receive instant grading, view their exam history, and print certificates for successfully completed programs at any time. Monthly notifications will be sent to participants notifying you of new courses available on the site.